News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. stocks slid, Dow down 1.7% to a six-month low as Iran conflict risk and rising oil deepen a market correction.
  • Private credit funds Blue Owl and HPS posted February's worst monthly returns since 2022, signaling stress in the leveraged loan market.
  • Kailera filed for a Nasdaq IPO, Yesway refiled for a U.S. IPO, and TRG's underwriter exercised part of its IPO over-allotment.
  • Entera Bio reported full-year 2025 results, filed a streamlined Phase 3 protocol for oral osteoporosis tablet EB613, and said cash funds near-term operations.
  • Analysts pitch buys on beaten-down names: Aurinia recommended after a management reset, while Kinsale is touted as a dip-buy despite a sharp pullback.
  • Bovespa fell 0.64% as real-estate and financials lagged, while Toronto gained 0.23% led by materials and energy.

Latest Articles

Truist Reaffirms Buy on Encompass Health After Strong Q4 Showing

Truist Reaffirms Buy on Encompass Health After Strong Q4 Showing

Truist Securities has kept a Buy rating and a $140 price target on Encompass Health Corp (EHC) after the company reported fourth-quarter results that beat several expectations. The target implies roughly 31% upside from the stock’s recent price, and the report highlights durable cash flow, expanding margins and constructive regulatory commentary as…

Truist Keeps Hold on Advance Auto Parts as Analysts Weigh Margin Targets

Truist Keeps Hold on Advance Auto Parts as Analysts Weigh Margin Targets

Truist Securities has affirmed a Hold rating and a $48.00 price target on Advance Auto Parts (AAP) ahead of the company’s impending quarterly report, while noting modest comparable-sales growth expectations and expressing low confidence in midterm operating margin projections. The stock has outperformed Truist’s target amid strong recent gains, and…

Veeva’s Oversold Bounce: A Trade for a Mid-Term Rebound

Veeva’s Oversold Bounce: A Trade for a Mid-Term Rebound

Veeva Systems is deep in oversold territory after a sharp pullback. Strong free cash flow, a fresh $2 billion buyback, and an expanding addressable market for regulated cloud workflows argue for a mean-reversion trade. This idea lays out a precise entry, stop and target with rationale and risks.

Lammy and Reed Publicly Back Starmer Amid Calls for Resignation

Lammy and Reed Publicly Back Starmer Amid Calls for Resignation

Deputy Prime Minister David Lammy and housing minister Steve Reed publicly affirmed their support for Prime Minister Keir Starmer on Monday, responding to a call for his resignation from Scottish Labour leader Anas Sarwar amid pressure linked to the Mandelson-Epstein scandal. Lammy and Reed urged continuity, stressing the need to remain focused on …

Hassett Says Lower Monthly Job Gains Likely as Demographics and Productivity Shift

Hassett Says Lower Monthly Job Gains Likely as Demographics and Productivity Shift

Kevin Hassett, director of the National Economic Council, told viewers that Americans should expect somewhat smaller monthly job creation figures in the months ahead. He attributed the anticipated decline to slowing population growth combined with accelerating productivity, and emphasized that such a pattern does not indicate overall economic weakn…

Clearmind Shares Dip After Second Cohort Safety Update for CMND-100

Clearmind Shares Dip After Second Cohort Safety Update for CMND-100

Clearmind Medicine Inc (NASDAQ:CMND) shares fell 6.6% on Monday after the company published safety findings from six additional patients in the second cohort of its Phase I/IIa study of CMND-100 for Alcohol Use Disorder. The data showed no serious adverse events and tolerability consistent with the first cohort, while investors appeared to react ne…